Ulcerative Colitis (UC) is a chronic, or long-lasting, disease that causes inflammation—irritation or swelling—and sores called ulcers on the inner lining of the large intestine.
The exact cause of Ulcerative Colitis (UC) is unknown. Researchers believe the following factors may play a role in causing ulcerative colitis: overactive intestinal immune system; genes; environment.
The severity of Ulcerative Colitis is classified as mild-to-moderate and moderate-to-severe.
DelveInsight's "Ulcerative Colitis (UC) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Ulcerative Colitis (UC) Market, historical and forecasted epidemiology, the pipeline insight as well as the Ulcerative Colitis (UC) market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Ulcerative Colitis (UC) market report also covers emerging drugs, current treatment practices, Ulcerative Colitis (UC) market shares of the individual therapies, current and forecasted Ulcerative Colitis (UC) Market Size segmented by seven major markets. The report provides a detailed current Ulcerative Colitis (UC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Ulcerative Colitis (UC) Market key facts
As per the study conducted by Whitney D. Lynch et al. (2019), Ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year. Its prevalence is 156 to 291 cases per 100,000 persons per year.
As per the study conducted by Gary R. Lichtenstein et al. (2015), in North America, the incidence of Ulcerative Colitis (UC) is 8 to 20 cases per 100,000 people, and the prevalence is 120 to 250 cases per 100,000 people.
Ulcerative Colitis (UC) Market Size and Growth Analysis
The Ulcerative Colitis (UC) market analysis section of the report helps to build the detailed comprehension of the historic, current and forecasted Ulcerative Colitis (UC) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Ulcerative Colitis (UC) market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Ulcerative Colitis (UC) Epidemiology Forecast
The Ulcerative Colitis (UC) epidemiology section covers insights about historical and current Ulcerative Colitis (UC) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognize the causes of current and forecasted Ulcerative Colitis (UC) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Ulcerative Colitis (UC) Pipeline Analysis and Key Companies
The Ulcerative Colitis (UC) Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis (UC) market or expected to get launched in the market during the study period. The analysis covers the Ulcerative Colitis (UC) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the Ulcerative Colitis (UC) drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Ulcerative Colitis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period.
Some of the Key Ulcerative Colitis (UC) companies include:
Landos Biopharma
Novartis Pharmaceuticals
Palobiofarma
Seres Therapeutics
Salix Pharmaceuticals
Shire
And many others.